(UroToday.com) In this discussion, Brandon Mahal discussed prostate cancer disparities, systemic racism, and precision medicine in prostate cancer disparities. There are well-known established prostate cancer risk factors, including age, family history, and race, which could stem from racism.Systemic (institutional) racism is a form of racism that is embedded in the everyday operation of society. It produces […]
(UroToday.com) Following Dr. Morgan’s presentation during the Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes session at the 2020 Society of Urologic Oncology (SUO) annual meeting, Dr. Evan Yu presented on the changing landscape of treatment for men with metastatic castration-resistant prostate cancer (mCRPC).
(UroToday.com) Dr. Scott Eggener took the “pro” side and Dr. Sia Daneshmand took the “con” side a debate about the value of minimally invasive retroperitoneal lymph node dissection (RPLND) for germ cell tumor.
(UroToday.com) In a stand-alone session at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, titled Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes, Dr. Alicia Morgans covered data on the rapidly evolving landscape of systemic therapy for patients with advanced prostate cancer including, […]
(UroToday.com) MK-6482 (aka belzutifan or PT2977), a small-molecule inhibitor of HIF-2α, was tested in a phase II trial presented by Dr. Ramaprasad Srinavasan at the 2020 Society of Urologic Oncology Best of Kidney Cancer poster session.
(UroToday.com) During the kidney cancer session during the Society of Urologic Oncology (SUO), Dr. Cristiane Bergerot from the City of Hope provided a comprehensive overview of the interplay between psychosocial factors and renal cell carcinoma. The psychosocial effects of renal cell carcinoma (RCC) are profound, with 20% of patients experiencing depression and 30% experiencing anxiety. […]
(UroToday.com) In the first Kidney Cancer session of this year’s Society of Urologic Oncology virtual annual meeting, Dr. John Gore discussed economic considerations in the care of patients with kidney cancer.
(UroToday.com) The landscape surrounding cytoreductive nephrectomy has been rapidly evolving over the last two decades in parallel to the growth of the immunotherapy armamentarium. During the kidney cancer session at the Society of Urologic Oncology (SUO, Dr. Jose Karam from MD Anderson Cancer Center presented a comprehensive look at this space and ways to improve […]
(UroToday.com) This year the Society of Urologic Oncology (SUO) honored Dr. Eila Skinner the Thomas A. Stamey Research Professor of Urology and Chair of the Department of Urology at Stanford University with the Huggins award. The award is named after Charles B. Huggins, MD, who won the Nobel Prize in 1966 for his landmark work in […]
(UroToday.com) The majority of the “Advances in prostate cancer diagnosis” session on Thursday of the 2020 Annual Meeting of the Society of Urologic Oncology (SUO) was dedicated to imaging with a strong focus on prostate-specific membrane antigen (PSMA). The United States Food and Drug Administration (FDA) approved Gallium 68 PSMA-11 as the first drug for PET […]
